As we mentioned yesterday, due to Dechert’s involvement in litigation concerning the drug at issue in Pliva, Inc. v. Mensing, No. 09–993, slip op. (U.S. June 23, 2011), we can’t comment on the case.

But some other people have. Here’s a wrap up of what other legal types (not the press) have said.

The FDA Law Blog channels Harry Carey, “Holy Cow!” Generics win.

PharmaExec focused on the dissent’s claim that preemption “makes generics more dangerous.”

The Wall Street Journal’s Law Blog called it a “red letter day” for generic manufacturers. The Journal’s Health Blog mentioned the case, but didn’t have all that much to say.